PA · EQS.PA
Equasens S.A.
- Sector
- Healthcare · Medical - Healthcare Information Services
- Headquarters
- Villers-lès-Nancy 54601
- Website
- pharmagest.com
Price · as of 2024-12-31
$37.50
Market cap 522.34M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $45.01 | +20.03% |
| Intrinsic Value(DCF) | $17.70 | -52.8% |
| Graham-Dodd Method(GD) | $1.76 | -95.3% |
| Graham Formula(GF) | $16.20 | -56.79% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $6.62 | $82.81 | $1.06 | $26.33 | |
| 2011 | $6.91 | $28.84 | $28.70 | $1.45 | $10.82 |
| 2012 | $10.84 | $28.63 | $37.51 | $1.67 | $17.47 |
| 2013 | $16.19 | $44.46 | $8.12 | $2.07 | $12.87 |
| 2014 | $19.60 | $29.10 | $6.49 | $1.64 | $10.19 |
| 2015 | $19.27 | $29.59 | $6.28 | $1.75 | $8.90 |
| 2016 | $29.85 | $36.18 | $9.99 | $2.62 | $28.23 |
| 2017 | $49.93 | $43.00 | $10.43 | $2.20 | $13.87 |
| 2018 | $51.65 | $47.52 | $26.90 | $1.79 | $37.54 |
| 2019 | $44.53 | $41.58 | $19.25 | $1.89 | $27.66 |
| 2020 | $88.44 | $62.74 | $27.41 | $1.86 | $32.95 |
| 2021 | $73.04 | $59.96 | $36.14 | $3.79 | $52.07 |
| 2022 | $66.98 | $57.68 | $49.87 | $6.80 | $56.96 |
| 2023 | $47.62 | $46.39 | $30.75 | $6.99 | $33.23 |
| 2024 | $34.64 | $45.01 | $6.31 | $1.76 | $16.20 |
AI valuation
Our deep-learning model estimates Equasens S.A.'s (EQS.PA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $45.01
- Current price
- $37.50
- AI upside
- +20.03%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$17.70
-52.8% upside
Graham-Dodd
$1.76
-95.3% upside
Graham Formula
$16.20
-56.79% upside
About Equasens S.A.
Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker solutions for pharmacists' business processes; and solutions for energizing the customer relationship with pharmacists comprising OffiTag, OffiTouch, OffiMédia, OffiConnect, automation systems, and customer loyalty programs. The company also provides My Pilot, an analytics and management tool; OffiLearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, Multimeds, Automeds, and OffiTéléconsult, as well as pharmaceutical record and shared medical record services. In addition, it offers a ULTIMATE, a system combining optimized pharmacy management and improved patient support; FARMACLICK, a protocol for communications between pharmacies and wholesalers-distributors; DIFARM, a solution for wholesalers-distributors; PHARE, a retail management tool; SOPHIA, a pharmacy management application; OffiMédia POS display; eNephro to enhance the care of chronic renal failure patients; and TPE Pilot, a web-based application that simplifies the management and sharing of patient education programs. Further, the company provides NOVIACARE; CARELIB Domicile; CARELIB EHPAD; KAPELSE solutions; TITAN solutions; ANTHADINE software and MOBISOINS mobile tool; MICROSOINS, an in-home nursing care solution; and LOGICLIC. Additionally, it offers AXIGATE solutions to manage the entire patient care pathway; CHORUS platform; medical telesecretarial services for healthcare professionals; and equipment lease financing solutions. The company was incorporated in 1996 and is based in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
- CEO
- Denis Supplisson
- Employees
- 1.27K
- Beta
- 0.86
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($17.70 ÷ $37.50) − 1 = -52.8% (DCF, example).